Prokinetic activity of nizatidine: Implications for the management of patients with gastroesophageal reflux disease

Clinical Therapeutics

Volumn 21, Issue 12, 1999, Pages 2038-2046

  Zarling, Edwin J ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gastric emptying; Nizatidine; Prokinetic

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; NEOSTIGMINE; NIZATIDINE; PROKINETIC AGENT;

COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL REFLUX; REVIEW; STOMACH ACID SECRETION; STOMACH EMPTYING;

EID: 0033400632     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)87235-5     Document Type: Article

References (26)

1. 1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis. 1976;21:953-956.
2. 2. Zarling EJ. A review of reflux esophagitis around the world. World J Gastroenterol. 1998;4:280-284.
3. 3. Castell DO, Brunton SA, Earnest DL, et al. GERD: Management algorithms for the primary care physician and the specialist. Pract Gastroenterol. 1999;23:20-44.
4. 4. Kahrilas PJ, Dodds WJ, Hogan WJ, et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986; 91:897-904.
5. 5. Mittal RK, Balaban DH. The esophagogastric junction. N Engl J Med. 1997; 336:924-932.
6. 6. Mason RJ, Ritter MP, Gadenstatter M, et al. Association of lower esophageal sphincter length with postprandial gastroesophageal reflux. Gastroenterology. 1997;112:A1458. Abstract.
7. 7. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology. 1995;109: 601-610.
8. 8. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut. 1988;29:1020-1028.
9. 9. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reflux. Gastroenterology. 1981; 80:285-291.
10. 10. Soykan I, Lin Z, Jones S, et al. Gastric myoelectrical activity, gastric emptying and correlations with dyspepsia symptoms in patients with gastroesophageal reflux. J Investig Med. 1997;45:483-487.
11. 11. DeVault KR, Castell DO, for the Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med. 1995;155:2165-2173.
12. 12. Castell DO, Brunton SA, Earnest DL, et al. GERD: Management algorithms for the primary care physician and the specialist. Pract Gastroenterol. 1998;22: 18-46.
13. 13. Inauen W, Emde C, Weber B, et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: A 24 hour ambulatory combined pH and manometry study. Gut. 1993;34:1025-1031.
14. 14. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med. 1995;333:1106-1110.
15. 15. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metochlopramide induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153:1469-1475.
16. 16. Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride diltiazem interaction. Pharmacotherapy. 1998;18:381-385.
17. 2 receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1993;264:152-157.
18. 2 receptor antagonists on gastrointestinal motility and gastric emptying. J Smooth Muscle Res. 1993; 29:131-142.
19. 19. Kaneko H, Mitsuma T, Uchida K, et al. Nizatidine accelerates gastric emptying of a solid meal in rats. Dig Dis Sci. 1995; 40:2043-2051.
20. 20. Ueki S, Matsunaga Y, Yoneta T, et al. Gastroprokinetic activity of nizatidine during the digestive state in the dog and rat. Arzneim-Forsch Drug Res. 1999;49:618-625.
21. 21. Harasawa S, Miwa T. The effect of nizatidine on gastric emptying and plasma gastrin concentration in patients with peptic ulcer. Jpn Pharmacol Ther. 1993;21:321-328.
22. 22. Chey WD, Hasler W, Kim M, Owyang C. Suppression of gastric acid secretion corrects the prolongation of migrating motor complex duration in patients with gastroesophageal reflux. Gastroenterology. 1995;108:A582. Abstract.
23. 23. Parkman HP, Pagano AP, Ryan JP. Ranitidine and nizatidine stimulate antral smooth muscle contractility via excitatory cholinergic mechanisms. Dig Dis Sci. 1998;43:497-505.
24. 2 receptor antagonist nizatidine (LY 139037) on the guinea pig ileum. J Pharmacobiodynam. 1987;10: 669-672.
25. 2 receptor antagonist, on gastrointestinal motility function. J Smooth Muscle Res. 1991; 21:337-338.
26. 2 receptor antagonists cimetidine, ranitidine, famotidine and nizatidine on the rabbit stomach fundus and sigmoid colon. J Pharmacobiodynam. 1992;15:561-565.